Paul Stoffels is the new Chief Executive Officer (CEO) of Galapagos Nv as of April 1, 2022. The same company, specializing in the development and marketing of small molecules with new modes of action, announces the appointment of Stoffels. He succeeds the current CEO and co-founder Onno van de Stolpe who had already announced his retirement. Paul Stoffels has significant experience in the research and development of innovative molecules and in the biotech and pharmaceutical sectors, where he has held various roles in different therapeutic areas, Galapagos reports in a statement. “We are very happy to announce that Paul Stoffels will be our new CEO. Given his excellent experience in research and development as well as in management, his vast network of relationships in the pharmaceutical world, together with his deep understanding of the points of strength and potential of Galapagos, we are convinced that Paul has the right qualifications to lead the company, “said Raj Parekh, chairman of Galapagos.” We want to express our gratitude and deep appreciation to Onno, who founded the company in 1999 and worked tirelessly on its development making it a European biotech with a differentiated pipeline and a first product on the market. “” My 23 years at the helm of this company has been an incredible journey and I could not be more honored to hand over the helm to Paul. As the founder and board member of the company early in his life, Paul has a deep understanding of our roots and who we are today, “added Onno van de Stolpe. “I firmly believe that Paul’s strategic and inspirational leadership, coupled with his great knowledge of both the pharmaceutical sector and Galapagos, make him the next best CEO, capable of creating extraordinary value for all stakeholders, including investors, shareholders and patients” . “I was personally involved by Crucell and Tibotec in the foundation of Galapagos in 1999 – commented Paul Stoffels – and I followed the company all the way that led it to be a full-fledged biopharmaceutical, as it is. today. I am attracted by its entrepreneurial culture and constant commitment to innovation, its strong research and development capabilities and growing commercial footprint. I am convinced that the solid financial resources and long-term partnership with Gilead, give Galapagos potential and I am thrilled and honored to have been appointed CEO. I want to express my respect and appreciation to Onno, who built or successfully the company, and led a start-up to become an independent, publicly traded company. I will remain faithful to the company’s mission to develop drugs with new mechanisms of action for patients who need new treatment options. ”Stoffels – the note continues – was previously Vice President of the Executive Committee and Chief Scientific Officer of J&J, where he led the innovative transformation of the entire company starting with the research programs and development of the product pipeline, discovering and developing high impact solutions, including the single dose Covid-19 vaccine, made in record time. Prior to that, he was J&J Chairman pharmaceuticals globally: under his leadership the company significantly rejuvenated its product pipeline and adopted a transformative R&D operating model, leading to the launch of 25 innovative medicines. all over the world. He joined J&J in 2002, with the acquisition of Virco and Tibotec, of which he was CEO and President respectively, and led the development of several innovative products for the treatment of HIV. Galapagos was founded in 1999 as a joint venture between Crucell and Tibotec and Paul was a member of the Galapagos board of directors from its founding until 2002. Stoffels studied medicine at the University of Diepenbeek and the University of Antwerp, Belgium, and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.